Top news
Why Biogen may be sitting on the most lucrative product in pharmaceutical history
By Adam Feuerstein & Damian Garde
Biogen's shockingly broad Aduhelm label—and $56K price—set up a $10B launch, analysts say
By Noah Higgins-Dunn
Biogen CEO says $56,000 annually for Alzheimer’s drug is 'fair,' promises not to hike price for at least 4 years
By Berkeley Lovelace & Berkeley Lovelace Jr.
All coverage
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients
By Julie Steenhuysen & Deena Beasley
In controversial decision, FDA approves first new Alzheimer's disease drug in nearly 20 years
By Jacqueline Howard
Alzheimer's drug from Biogen wins US approval
By Nikou Asgari
New Alzheimer’s drug is 1st of its kind to be FDA approved
By Sony Salzman & Deepak Ramanathan
Alzheimer's Drug Poses a Dilemma for the F.D.A. (Published 2021)
By Pam Belluck & Rebecca Robbins
FDA Approves First New Alzheimer's Drug in Nearly Two Decades
By Joseph Walker
Aducanumab: FDA Approves Controversial Alzheimer's Drug
By Scott Hensley
Biogen shares surge 38% after FDA approves Alzheimer's drug, the first new therapy for the disease in nearly two decades
By Berkeley Lovelace & Berkeley Lovelace Jr.
Alzheimer's Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense (Published 2021)
By Pam Belluck & Rebecca Robbins
F.D.A. Approves Alzheimer's Drug Despite Fierce Debate Over Whether It Works (Published 2021)
By Pam Belluck & Rebecca Robbins